Chelsea Therapeutics (CHTP) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-8.07M
Non-cash stock-based compensation	706.06K
Depreciation and amortization	16.08K
Stock issued for license agreement	0
Non-cash interest expense	0
Gain on disposition of assets	0
Fair value of warrants for finder's agreement	0
Prepaid contract research and manufacturing expenses, other prepaid expenses and other assets	-108.89K
Accounts payable, accrued contract research and manufacturing expenses and other accrued expenses
Accrued compensation and related expenses	234.81K
Net cash used in operating activities	-6.73M
Acquisitions of property and equipment	0
Proceeds from sale of assets	0
Purchases of short-term investments	0
Redemptions and sales of short-term investments	0
Security deposits
Net cash (used in) provided by investing activities	-1.5M
Proceeds from borrowings from affiliate	0
Borrowings from (repayments of) line of credit
Proceeds from exercise of stock options	594
Proceeds from exercise of common stock warrants	0
Recapitalization of the Company	0
Proceeds from sales of equity securities, net of issuance costs	0
Receipt of recovery of short-swing profits
Receipt of cash for stock subscription receivable	0
Net cash provided by financing activities	594
Net (decrease) increase in cash and cash equivalents	-8.23M
Cash and cash equivalents, beginning of period	45.32M
Cash and cash equivalents, end of period	37.09M
Cash paid for interest	0

Entities mentioned with CHTP

View All Entities